CERVIX | CERVICAL SCREENING [ISSN 1804-087X]
česky | english | sitemap


PARTNERS AND EXPERT GUARANTEE
 
Czech Gynaecological and Obstetrical Society | Ministry of Health | Institute of Biostatistics and Analyses, Masaryk University
GRANT SUPPORT OF THE PROJECT
 
GlaxoSmithKline     Roche |

Other sources of information
Cervical cytology (in Czech)www.cipek.cz
Cervical cytology
 
Cancer Screening in the European Unionec.europa.eu
Cancer Screening in the European Union (2017)
[ 10,6 MB]
 
SVOD - Epidemiology of malignant tumours in the Czech Republicwww.svod.cz
Epidemiology of malignant tumours
in the Czech Republic
 
NCI Bethesda System
HPV College

 

Studies reveal potential of HPV vaccine to substantially reduce incidence of cervical cancer and suggest screening programmes could be modified

The bivalent human papillomavirus (HPV) vaccine (Cervarix, GlaxoSmithKline) offers excellent protection against the more serious immediate precursor to invasive cervical cancer (ICC), particularly when given to young adolescent girls before they become sexually active. The findings of two studies published in The Lancet Oncology, also show that the vaccine partially protects against four other cancer-causing HPV types not targeted by the formulation, that together with HPV16/18, cause about 85% of cervical cancer worldwide.


"Provided that organised vaccination programmes achieve high coverage in early adolescents before sexual debut, HPV vaccination has the potential to substantially reduce the incidence of cervical cancer, probably allowing modification of screening programmes... when conducted alongside vaccination strategies", explains one of the lead authors, Matti Lehtinen from the University of Tampere in Finland.

The bivalent vaccine targets HPV types 16 and 18 that are responsible for about 70% of cervical cancers. Most studies of vaccine efficacy have focused on prevention of cervical intraepithelial neoplasia 2 (CIN2) or higher. However, CIN3 is generally believed to be a more reproducible and predictive endpoint than CIN2, and often progresses to ICC.

Read the whole article at ecancermedicalscience

Reference

  1. Lehtinen, M., Paavonen, J., et al. (2011). Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial The Lancet Oncology DOI: 10.1016/S1470-2045(11)70286-8
  2. Wheeler, C., Castellsague, X. et al. (2011). Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Lancet Oncology DOI: 10.1016/S1470-2045(11)70287-X

9.11.2011 ecancermedicalscience


Back